{Reference Type}: Journal Article
{Title}: Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes.
{Author}: Zou S;Zhang L;Jiang C;Li F;Yang Y;Deng X;Zhang J;Chen H;Jiang L;Cheng X;Deng L;Lin L;Shen B;Wen C;Zhan Q;
{Journal}: Cancer Lett
{Volume}: 599
{Issue}: 0
{Year}: 2024 Sep 1
{Factor}: 9.756
{DOI}: 10.1016/j.canlet.2024.217134
{Abstract}: Despite many studies focusing on the prognostic biomarkers in pancreatic adenocarcinomas (PAADs), there is ill-informed about the relationships between their genomic features and immune characteristics. Herein, we deeply investigated the involvement of major driver mutation subtypes with immunophenotypes impacting PAAD outcomes. Based on public data analyses of RNA expression-based immune subtypes in PAAD, in contrast to KRAS G12D & TP53 co-mutant patients with poor outcomes, the best immune subtype C3 (inflammatory) characterized by high Th1/Th2 ratio was relatively enriched in KRASnon-G12DTP53wt patients with better survival, whereas the inferior subtype C2 (IFN-γ dominant) with low Th1/Th2 ratio was more common in the former than in the latter. Moreover, contrary to the highly immunosuppressive microenvironment (high Treg, high ratio of Treg to tumor-specific CD4+ T cell) in KRASG12DTP53mut patients, KRASG12VTP53wt individuals exhibited an inflamed context profiled by multiplex immunohistochemistry. It could be responsible for their outstanding survival advantage over others in postsurgical PAAD patients receiving adjuvant chemotherapy as shown by our cohort. Together, KRASG12VTP53wt may be a promising biomarker for prognostic evaluation and screening certain candidates with PAAD to get desirable survival benefit from adjuvant chemotherapy.